Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?
Cesario V. Borlongan, et al., STEM CELLS Translational Medicine
Almost four decades of laboratory research have shown safety and efficacy of stem cells in stroke animals. Yet, this cell-based regenerative medicine remains designated as “experimental" in the clinic. Equally disappointing, two recently concluded clinical trials indicated stem cells are safe but not effective in stroke patients. These failed clinical trials may be due to a loss in translation of optimal laboratory stem cell transplantation protocols to clinical trial designs. A concerted effort between basic scientists and clinicians, with NIH and Food and Drug Administration guidance, is key to realizing the safe and effective translation of stem cell therapy for stroke.
IDO1 Maintains Pluripotency of Primed Human Embryonic Stem Cells by Promoting Glycolysis
Xin Liu, et al., STEM CELLS
Indoleamine 2,3-dioxygenase 1 (IDO1) has been known to play important metabolic roles in the kynurenine pathway. This study discovered that IDO1 is required to maintain glycolysis in human embryonic stem cells (hESCs), and therefore maintains pluripotency of hESCs. These findings further shed light on the link between pluripotency and cancer, since cancer cells have a similar metabolic process as stem cells.
A study reports that extracellular vesicles from transplanted human cardiac progenitor cells drive the regenerative response following myocardial infarction
Researchers describes a means to expand HFSCs that engraft after intravascular administration in an autologous-like murine model of in-utero transplantation
Researchers confirm that α-synuclein can pass from the gut to the brain via the vagus nerve to induce Parkinson’s-like symptoms using a new mouse model